prostate cancer Archives

Polygenic “scores” may improve cancer screening

Oct. 31, 2023—Accounting for genetic variability in biomarkers not associated with cancer risk could avoid unnecessary diagnostic procedures, Vanderbilt researchers found.

conceptual image of word "cancer" hidden in dna code

International workgroup of geneticists issues CHEK2 guidelines

Jul. 26, 2023—International workgroup issues additional guidance on how to manage patients who carry inherited CHEK2 gene mutations that put them at a higher risk for cancer.

More U.S. prostate cancer patients choosing active surveillance

Apr. 3, 2023—A Vanderbilt study found the number of prostate cancer patients in the U.S. choosing active surveillance over surgery or radiation has rapidly increased since 2010, rising from 16% to 60% for low-risk patients and from 8% to 22% for patients with favorable intermediate-risk cancers.

Research by Mingjian Shi, PhD, left, Jonathan Mosley, MD, PhD, Kerry Schaffer, MD, MSCI, and colleagues found that polygenic risk score does not improve prediction of aggressive prostate cancer.

Study evaluates polygenic risk score for prostate cancer risk prediction

Mar. 16, 2023—A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.

Study reveals pathways for aggressive prostate cancer subtype

Oct. 27, 2022—Research from Vanderbilt-Ingram Cancer Center has revealed new information about the molecular pathways of cribriform prostate cancer.

Scott Sullivant is one of the many patients being helped through VUMC’s REACH for Survivorship Clinic.

Clinic helps patients prepare to move beyond prostate cancer

Aug. 4, 2022—Vanderbilt's REACH for Survivorship Clinic takes a holistic approach to help treat prostate cancer patients.

Prostate cancer treatment regret

Dec. 9, 2021—Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity.

Combo therapy slows prostate cancer

Oct. 19, 2021—A new combination treatment showed promise in slowing the growth of castration-resistant prostate cancer in animal models, Vanderbilt researchers discovered.

Clinical trial tests ATR inhibitor in difficult-to-treat cancers

Sep. 23, 2021— by Tom Wilemon A clinical trial has been launched to test a new targeted therapy in patients with advanced and difficult-to-treat cancers. Satya Das, MD, MSCI, assistant professor of Medicine at Vanderbilt-Ingram Cancer Center (VICC), is the national principal investigator for the trial (NCT04514497) that is now enrolling people with metastatic small cell lung...